Januvia off to good start, data shows
Merck’s new first-in-class diabetes drug Januvia is off to a strong start, according to data from ImpactRx, a market research ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.